Richard Zang
Publications by Year
Research Areas
Cancer Mechanisms and Therapy, Melanoma and MAPK Pathways, Advanced Breast Cancer Therapies, Colorectal Cancer Treatments and Studies, Computational Drug Discovery Methods
Most-Cited Works
- → Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research(2014)224 cited
- → Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity(2019)185 cited
- → An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance(2023)174 cited
- → Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling(2020)169 cited
- → Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities–Minireview(2019)118 cited
- → Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers(2014)111 cited
- → Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)(2019)104 cited
- → Developments in MLflow(2020)97 cited
- → Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities(2019)87 cited
- → Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies(2015)74 cited